NeRRe Raises £20M to Develop Orvepitant for IPF Chronic Cough

NeRRe Raises £20M to Develop Orvepitant for IPF Chronic Cough

299180

NeRRe Raises £20M to Develop Orvepitant for IPF Chronic Cough

NeRRe Therapeutics has raised £20 million (nearly $28 million) to develop orvepitant as a treatment for the chronic cough that can impact quality of life for people with idiopathic pulmonary fibrosis (IPF). Orvepitant’s efficacy has been demonstrated in patients with refractory or unexplained chronic cough associated with reflex hypersensitivity disorders. Now, the company plans to evaluate its potential in treating chronic cough caused by IPF — for which there are no approved medications. “After demonstrating…

You must be logged in to read/download the full post.